Published in Hepatitis Weekly, August 22nd, 2005
"Combination therapy of interferon-alpha (IFN alpha) and the oral nucleoside analog ribavirin is the standard treatment for individuals suffering from hepatitis C virus (HCV) infection. Several studies have shown combination therapy of IFN and antioxidants is therapeutically beneficial in these patients," researchers in Israel report.
"Ursodeoxycholic acid (UDCA) is a hydrophilic bile acid possessing antioxidant properties. This study evaluated the clinical outcome and extent of oxidative stress in a group of non-responding and disease-relapsed HCV patients treated with IFN...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.